Adicet Bio (1IJ) Stock Overview
A clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
1IJ Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Adicet Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.81 |
| 52 Week High | US$17.66 |
| 52 Week Low | US$5.38 |
| Beta | 1.61 |
| 1 Month Change | 12.60% |
| 3 Month Change | -39.54% |
| 1 Year Change | -47.42% |
| 3 Year Change | -94.75% |
| 5 Year Change | -95.79% |
| Change since IPO | -96.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1IJ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.7% | 4.5% | 0.6% |
| 1Y | -47.4% | -9.4% | 10.7% |
Return vs Industry: 1IJ underperformed the German Biotechs industry which returned -8.9% over the past year.
Return vs Market: 1IJ underperformed the German Market which returned 9.9% over the past year.
Price Volatility
| 1IJ volatility | |
|---|---|
| 1IJ Average Weekly Movement | 14.6% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 1IJ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1IJ's weekly volatility has decreased from 20% to 15% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 152 | Chen Schor | www.adicetbio.com |
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company’s lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin’s lymphoma.
Adicet Bio, Inc. Fundamentals Summary
| 1IJ fundamental statistics | |
|---|---|
| Market cap | €71.79m |
| Earnings (TTM) | -€96.81m |
| Revenue (TTM) | n/a |
Is 1IJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1IJ income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$115.01m |
| Earnings | -US$115.01m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.38 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 1IJ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/26 03:02 |
| End of Day Share Price | 2026/01/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Adicet Bio, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Zelin | B. Riley Securities, Inc. |
| John Newman | Canaccord Genuity |
| Michael Schmidt | Guggenheim Securities, LLC |